{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253156,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:13:42Z","timestamp":1768320822000},"page":"e421-e429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed\/Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Jean M.","family":"Clement","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":false,"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0001","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2023-190022","article-title":"Updated trends in incidence and survival of mantle cell lymphoma from 2000 to 2020","volume":"142","author":"Arora","year":"2023","journal-title":"Blood"},{"issue":"10441","key":"10.1016\/j.clml.2026.01.008_bib0002","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"The Lancet"},{"issue":"26","key":"10.1016\/j.clml.2026.01.008_bib0003","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"10514","key":"10.1016\/j.clml.2026.01.008_bib0004","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.01.008_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.01.008_bib0006","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.01.008_bib0007","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic index in randomized trials of the European mantle-cell lymphoma network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.01.008_bib0008","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.01.008_bib0009","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2026.01.008_bib0010","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.01.008_bib0011","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.01.008_bib0012","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.17513","article-title":"Treatment patterns and outcomes of unfit and elderly patients with mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis","volume":"194","author":"Rampotas","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2026.01.008_bib0013","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2026.01.008_bib0014","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2026.01.008_bib0015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0046-8177(95)90090-X","article-title":"Expression of cyclin D1 protein in centrocytic\/mantle cell lymphomas with and without rearrangement of the BCL1\/cyclin D1 gene","volume":"26","author":"Swerdlow","year":"1995","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.clml.2026.01.008_bib0016","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non\u2013B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.01.008_bib0017","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling","volume":"113","author":"Be\u00e0","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.01.008_bib0018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03bab activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.01.008_bib0019","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2026.01.008_bib0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.2023022351","article-title":"Unraveling MCL biology to understand resistance and identify vulnerabilities","volume":"145","author":"Sarkozy","year":"2025","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.01.008_bib0021","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"issue":"10020","key":"10.1016\/j.clml.2026.01.008_bib0022","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.clml.2026.01.008_bib0023","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2026.01.008_bib0024","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.01.008_bib0025","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with Ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.clml.2026.01.008_bib0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10121","key":"10.1016\/j.clml.2026.01.008_bib0027","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.clml.2026.01.008_bib0028","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.clml.2026.01.008_bib0029","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with Zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"21","key":"10.1016\/j.clml.2026.01.008_bib0030","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2026.01.008_bib0031","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2023-191921","article-title":"Ibrutinib combined with Venetoclax in patients with relapsed\/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.01.008_bib0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.01.008_bib0033","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.01.008_bib0034","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2026.01.008_bib0035","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.01.008_bib0036","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"issue":"4\u20135","key":"10.1016\/j.clml.2026.01.008_bib0037","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/path.6434","article-title":"Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy","volume":"266","author":"L\u00e1szl\u00f3","year":"2025","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.clml.2026.01.008_bib0038","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review Study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.01.008_bib0039","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.01.008_bib0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2026.01.008_bib0041","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.01.008_bib0042","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.01.008_bib0043","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.01.008_bib0044","first-page":"S207","volume":"31","author":"Wang","year":"2025","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"issue":"20","key":"10.1016\/j.clml.2026.01.008_bib0045","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.01.008_bib0046","unstructured":"Optimizing post\u2013chimeric antigen receptor (CAR) T cell monitoring: evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience. - ASCO. Accessed November 13, 2025. https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495856"},{"issue":"24","key":"10.1016\/j.clml.2026.01.008_bib0047","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0048","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-137237","article-title":"LOXO-305, A next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and other non-hodgkin lymphomas: results from the phase 1\/2 BRUIN study","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.clml.2026.01.008_bib0049","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clml.2026.01.008_bib0050","article-title":"BRUIN MCL-321: a phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor na\u00efve mantle cell lymphoma","author":"Eyre","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.01.008_bib0051","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","article-title":"Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): updated analysis from a phase I\/II study","volume":"42","author":"Phillips","year":"2024","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.clml.2026.01.008_bib0052","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.008_bib0053","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.01.008_bib0054","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1002\/ajh.24854","article-title":"Long-term analysis of phase II studies of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Witzig","year":"2017","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2026.01.008_bib0055","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"j Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2026.01.008_bib0056","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter Phase II study of Bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.008_bib0057","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.clml.2026.01.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102221","article-title":"Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1\/2 trial of the European MCL network (SAKK 36\/13)","volume":"64","author":"Novak","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"6","key":"10.1016\/j.clml.2026.01.008_bib0059","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41375-024-02254-2","article-title":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma\u2014A randomized, open-label phase III trial of the European mantle cell lymphoma network","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2026.01.008_bib0060","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate Temsirolimus compared with Investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.008_bib0061","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2026.01.008_bib0062","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2021.39.15_suppl.7518","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: safety profile and antitumor activity","volume":"39","author":"Clausen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2026.01.008_bib0063","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with Mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.01.008_bib0064","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1016\/S2152-2650(25)02485-1","article-title":"MCL-1493: fixed-duration outpatient subcutaneous Mosunetuzumab + Polatuzumab Vedotin shows robust efficacy in a phase 2 study of relapsed\/refractory (R\/R) post-BTK inhibitor mantle cell lymphoma (MCL)","volume":"25","author":"Wang","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0065","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration Mosunetuzumab plus Polatuzumab Vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.01.008_bib0066","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0067","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1182\/blood-2022-168483","article-title":"Bruton\u2019s tyrosine kinase (BTK) degrader Nx-2127 exhibits lethal activity and synergy with venetoclax and BET protein inhibitor against MCL cells sensitive or resistant to covalent BTK inhibitors","volume":"140","author":"Fiskus","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.008_bib0068","unstructured":"Inc MG. BEXOBRUTIDEG (NX-5948), A NOVEL BRUTON\u2019S TYROSINE KINASE (BTK)... by Zulfa Omer. Accessed November 13, 2025. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159978\/zulfa.omer.bexobrutideg.28nx-594829.a.novel.bruton.s.tyrosine.kinase.28btk29.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0069","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, First-in-Human study of the Bruton\u2019s tyrosine kinase (BTK) degrader bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0070","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1182\/blood-2024-205897","article-title":"Zilovertamab Vedotin monotherapy for patients with relapsed or refractory mantle cell lymphoma: cohort a of the multicenter, open-label, phase 2 Waveline-006 study","volume":"144","author":"Glimelius","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0071","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2024-205985","article-title":"Zilovertamab vedotin in combination with nemtabrutinib for patients with relapsed or refractory mantle cell lymphoma: cohort C of the open-label, phase 2 waveline-006 study","volume":"144","author":"Paszkiewicz-Kozik","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2026.01.008_bib0072","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.008_bib0073","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2024-202154","article-title":"Loncastuximab tesirine in combination with venetoclax is safe and shows efficacy in patients with relapsed\/refractory non hodgkin lymphoma","volume":"144","author":"Caimi","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.01.008_bib0074","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood.V116.21.1812.1812","article-title":"PI3K a selective inhibitor induces growth inhibition in mantle cell lymphoma","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.01.008_bib0075","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1038\/s41598-023-30148-3","article-title":"Roles of PI3K\u03b3 and PI3K\u03b4 in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3K\u03b3\/\u03b4 inhibitor duvelisib","volume":"13","author":"Till","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2026.01.008_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102131","article-title":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study","volume":"62","author":"Zinzani","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:16:45Z","timestamp":1776741405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265026000108"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed\/Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}